{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:42:38Z","timestamp":1790635358998,"version":"4.1.0"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"2024 PSM Guangdong Pharmaceutical Science Research Fund","award":["2024KP106"],"award-info":[{"award-number":["2024KP106"]}]},{"name":"2024 Guangdong Provincial universities characteristic innovation project","award":["2024KTSCX078"],"award-info":[{"award-number":["2024KTSCX078"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Long-acting Gonadotropin-releasing hormone analogs(GnRHa), including leuprolide, goserelin, histrelin, buserelin, triptorelin, have been widely used for a variety of diseases including prostate cancer, breast cancer, endometriosis, uterine leiomyomas, and central precocious puberty (CPP). However, their real-world safety profile differences have not been adequately compared.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Objective<\/jats:title>\n<jats:p>We aimed to investigate the adverse event (AE) profile differences of long-acting GnRHa reported by the US Food and Drug Administration Adverse Event Reporting System (FAERS).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Methods<\/jats:title>\n<jats:p>All indications were searched long-acting GnRHa, as primary suspect drugs, from FAERS data (January 2004 to September 2023). We performed disproportionality analyses by reporting odds ratios (ROR) and conducted univariate and multivariate logistical regression analyses to determine the odds ratio (OR) of serious AEs associated with long-acting GnRHa under different exposure factors.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Results<\/jats:title>\n<jats:p>Reproductive system and breast disorders accounted for the greatest proportion of adverse events among the five long-acting GnRHa formulations analyzed. Both buserelin and histrelin showed distinct adverse effect profiles, with buserelin demonstrating a higher incidence of gastrointestinal disorders and histrelin showing a greater propensity for psychiatric disorders. Logistic regression analysis revealed these five medications carried an elevated risk of significant medical events, and this risk was notably lower in pediatric patients (&lt;18 years) compared to adult populations (\u226518 years).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Significant disparities exist between the adverse event profiles of long-acting GnRHa. The identification of high-risk factors and the enhancement of AEs monitoring are crucial during clinical application.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0327842","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T17:42:17Z","timestamp":1752255737000},"page":"e0327842","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Adverse event profile differences among long-acting gonadotropin-releasing hormone analogs: A real-world, pharmacovigilance study"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2211-7895","authenticated-orcid":true,"given":"Yuting","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weitao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruilian","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2539-2294","authenticated-orcid":true,"given":"Huancun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"issue":"5","key":"pone.0327842.ref001","doi-asserted-by":"crossref","first-page":"497","DOI":"10.23736\/S0026-4784.18.04316-2","article-title":"Gonadotropin-releasing hormone analog therapeutics","volume":"70","author":"CL Newton","year":"2018","journal-title":"Minerva Ginecol"},{"issue":"5","key":"pone.0327842.ref002","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ctrv.2013.12.001","article-title":"Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials","volume":"40","author":"L Del Mastro","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"pone.0327842.ref003","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1089\/jwh.2017.6355","article-title":"The Role of Gonadotropin-Releasing-Hormone Analogues in the Treatment of Breast Cancer","volume":"27","author":"L Rossi","year":"2018","journal-title":"J Womens Health (Larchmt)"},{"issue":"11","key":"pone.0327842.ref004","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.21873\/anticanres.13850","article-title":"Radiotherapy Plus GnRH analogue versus high dose bicalutamide: a case control study","volume":"39","author":"M Buwenge","year":"2019","journal-title":"Anticancer Res"},{"issue":"2","key":"pone.0327842.ref005","first-page":"191","article-title":"Clinicopathological changes of uterine leiomyomas after GnRH agonist therapy","volume":"39","author":"C Grigoriadis","year":"2012","journal-title":"Clin Exp Obstet Gynecol"},{"issue":"3","key":"pone.0327842.ref006","first-page":"327","article-title":"Prolonged vaginal bleeding during central precocious puberty therapy with a long-acting gonadotropin-releasing hormone agonist","volume":"77","author":"A Yeshaya","year":"1998","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"3","key":"pone.0327842.ref007","doi-asserted-by":"crossref","first-page":"135","DOI":"10.6065\/apem.2014.19.3.135","article-title":"Significant adverse reactions to long-acting gonadotropin-releasing hormone agonists for the treatment of central precocious puberty and early onset puberty","volume":"19","author":"JW Lee","year":"2014","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"1","key":"pone.0327842.ref008","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000351028","article-title":"Occurrence of slipped capital femoral epiphysis in children undergoing gonadotropin-releasing hormone agonist therapy for the treatment of central precocious puberty","volume":"80","author":"M Inman","year":"2013","journal-title":"Horm Res Paediatr"},{"issue":"3","key":"pone.0327842.ref009","doi-asserted-by":"crossref","first-page":"365","DOI":"10.4274\/jcrpe.2212","article-title":"Pseudotumour Cerebri Presentation in a Child Under the Gonadotropin-Releasing Hormone Agonist Treatment","volume":"8","author":"\u00dc G\u00fcl","year":"2016","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"9","key":"pone.0327842.ref010","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1007\/s00467-014-2795-6","article-title":"Arterial hypertension during treatment with triptorelin in a child with Williams-Beuren syndrome","volume":"29","author":"E Siomou","year":"2014","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"pone.0327842.ref011","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1442-2042.2011.02886.x","article-title":"Life-threatening anaphylaxis to leuprorelin acetate depot: case report and review of the literature","volume":"19","author":"A Fujisaki","year":"2012","journal-title":"Int J Urol"},{"issue":"11","key":"pone.0327842.ref012","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/j.1600-0560.2012.01980.x","article-title":"Follicular mucinosis and mycosis-fungoides-like drug eruption due to leuprolide acetate: a case report and review","volume":"39","author":"SC Shalin","year":"2012","journal-title":"J Cutan Pathol"},{"issue":"22","key":"pone.0327842.ref013","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11864-021-00846-z","article-title":"Cardiovascular toxicities of androgen deprivation therapy","volume":"6","author":"AA Challa","year":"2021","journal-title":"Curr Treat Options Oncol"},{"issue":"7","key":"pone.0327842.ref014","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1080\/00016340600608717","article-title":"Leuprolide acetate-induced leukocytoclastic vasculitis","volume":"86","author":"BG Turk","year":"2007","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"9","key":"pone.0327842.ref015","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/17425255.2020.1789591","article-title":"Tolerability considerations for gonadotropin-releasing hormone analogues for endometriosis","volume":"16","author":"L Della Corte","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"pone.0327842.ref016","first-page":"1064","article-title":"Clinical evaluation of laparoscopic surgery combined with triptorelin acetate in patients with endometriosis and infertility","volume":"34","author":"H Xue","year":"2018","journal-title":"Pak J Med Sci"},{"issue":"4","key":"pone.0327842.ref017","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/andr.13533","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil","volume":"12","author":"Y Wang","year":"2024","journal-title":"Andrology"},{"key":"pone.0327842.ref018","doi-asserted-by":"crossref","first-page":"1333662","DOI":"10.3389\/fphar.2024.1333662","article-title":"A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system","volume":"15","author":"B Zhao","year":"2024","journal-title":"Front Pharmacol"},{"issue":"4","key":"pone.0327842.ref019","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/17425255.2023.2219390","article-title":"A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database","volume":"19","author":"H Yang","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"pone.0327842.ref020","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17425255.2023.2235267","article-title":"A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database","volume":"19","author":"B Zhao","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"pone.0327842.ref021","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1080\/14740338.2024.2410436","article-title":"A real-world pharmacovigilance study using disproportionality analysis of United States Food and Drug Administration Adverse Event Reporting System events for vinca alkaloids: comparing vinorelbine and Vincristine","volume":"23","author":"C Zhong","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"8","key":"pone.0327842.ref022","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40264-021-01082-y","article-title":"Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010-2019","volume":"44","author":"J Setyawan","year":"2021","journal-title":"Drug Saf"},{"issue":"6","key":"pone.0327842.ref023","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"J-L Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"pone.0327842.ref024","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijcard.2020.06.032","article-title":"Factors associated with bleeding events in patients on rivaroxaban for non-valvular atrial fibrillation: A real-world experience","volume":"320","author":"T Akhtar","year":"2020","journal-title":"Int J Cardiol"},{"issue":"4","key":"pone.0327842.ref025","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/cam4.2044","article-title":"Hormonal therapy in uterine sarcomas","volume":"8","author":"Y Zang","year":"2019","journal-title":"Cancer Med"},{"issue":"3","key":"pone.0327842.ref026","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/GCO.0000000000000701","article-title":"Suboptimal response to GnRH agonist trigger: causes and practical management","volume":"33","author":"P Humaidan","year":"2021","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"1","key":"pone.0327842.ref027","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/uog.18934","article-title":"Gonadotropin-releasing hormone agonists for ovarian protection during cancer chemotherapy: systematic review and meta-analysis","volume":"51","author":"JC Senra","year":"2018","journal-title":"Ultrasound Obstet Gynecol"},{"issue":"10","key":"pone.0327842.ref028","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1056\/NEJMoa1413204","article-title":"Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy","volume":"372","author":"HC Moore","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0327842.ref029","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/AOG.0000000000000964","article-title":"Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial","volume":"126","author":"AD DiVasta","year":"2015","journal-title":"Obstet Gynecol"},{"issue":"1","key":"pone.0327842.ref030","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12958-020-00586-z","article-title":"A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25\u2009mg) in combination with Tibolone add-back therapy in the management of chronic cyclical pelvic pain","volume":"18","author":"SM Alshehre","year":"2020","journal-title":"Reprod Biol Endocrinol"},{"key":"pone.0327842.ref031","doi-asserted-by":"crossref","first-page":"191967","DOI":"10.1155\/2014\/191967","article-title":"Medical treatments for endometriosis-associated pelvic pain","volume":"2014","author":"G Zito","year":"2014","journal-title":"Biomed Res Int"},{"issue":"7","key":"pone.0327842.ref032","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/jnr.24632","article-title":"Pharmacological sex hormone manipulation as a risk model for depression","volume":"98","author":"VG Frokjaer","year":"2020","journal-title":"J Neurosci Res"},{"issue":"4","key":"pone.0327842.ref033","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.22r14614","article-title":"What\u2019s stopping us? Using GnRH analogs with stable hormone addback in treatment-resistant premenstrual dysphoric disorder: Practical guidelines and risk-benefit analysis for long-term therapy","volume":"84","author":"M Wagner-Schuman","year":"2023","journal-title":"J Clin Psychiatry"},{"key":"pone.0327842.ref034","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0301-2115(96)02499-2","article-title":"Combined use of a long-acting gonadotropin-releasing hormone agonist and low-dose danazol in advanced stage endometriosis","volume":"68","author":"M Ugur","year":"1996","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"7","key":"pone.0327842.ref035","first-page":"301","article-title":"Injection-site granulomas due to the administration of leuprorelin acetate for the treatment of prostatic cancer","volume":"98","author":"M Shiota","year":"2007","journal-title":"Fukuoka igaku zasshi = Hukuoka acta medica"},{"key":"pone.0327842.ref036","first-page":"771","article-title":"Granuloma at the injection site of leuprorelin acetate: foreign body reaction to polylactic acid","volume":"134","author":"C Vieu","year":"2007","journal-title":"Ann Dermatol Venereol"},{"issue":"10","key":"pone.0327842.ref037","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1111\/1756-185X.14692","article-title":"Erythema nodosum caused by goserelin acetate sustained-release: case report and literature review","volume":"26","author":"F Meng","year":"2023","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"pone.0327842.ref038","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4274\/jcrpe.galenos.2021.2021.0205","article-title":"Vasculitis-like Palpable Purpuric Rash Induced by Decapeptyl in a Pediatric Patient Diagnosed Central Precocious Puberty","volume":"15","author":"N Galip","year":"2023","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"1","key":"pone.0327842.ref039","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000505329","article-title":"Management of Systemic Hypersensitivity Reactions to Gonadotropin-Releasing Hormone Analogues during Treatment of Central Precocious Puberty","volume":"93","author":"T Kirkgoz","year":"2020","journal-title":"Horm Res Paediatr"},{"issue":"3","key":"pone.0327842.ref040","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3109\/00365521.2014.958098","article-title":"Severe gastrointestinal dysmotility developed after treatment with gonadotropin-releasing hormone analogs","volume":"50","author":"L Cordeddu","year":"2015","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"pone.0327842.ref041","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/j.gastro.2006.10.036","article-title":"Chronic intestinal pseudo-obstruction due to buserelin-induced formation of anti-GnRH antibodies","volume":"132","author":"B Ohlsson","year":"2007","journal-title":"Gastroenterology"},{"issue":"4","key":"pone.0327842.ref042","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.fertnstert.2004.12.007","article-title":"Leuprolide acetate treatment with and without coadministration of tibolone in premenopausal women with menstrual cycle-related irritable bowel syndrome","volume":"83","author":"S Palomba","year":"2005","journal-title":"Fertil Steril"},{"issue":"6","key":"pone.0327842.ref043","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/BF02093778","article-title":"Effect of leuprolide acetate in patients with moderate to severe functional bowel disease. Double-blind, placebo-controlled study","volume":"39","author":"JR Mathias","year":"1994","journal-title":"Dig Dis Sci"},{"issue":"3","key":"pone.0327842.ref044","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0952-3278(91)90170-A","article-title":"Changes in thromboxane A2 generation and plasma lipid pattern in pseudomenopause induced by gonadotropin releasing hormone (GnRH) analogue buserelin","volume":"43","author":"S Pinto","year":"1991","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"202","key":"pone.0327842.ref045","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1097\/JU.0000000000000384","article-title":"Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease","volume":"6","author":"D Margel","year":"2019","journal-title":"J Urol"},{"issue":"4","key":"pone.0327842.ref046","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/s41391-022-00640-4","article-title":"Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: analysis of real-life data from Eudra-Vigilance and Food and Drug Administration databases entries","volume":"26","author":"A Cicione","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"pone.0327842.ref047","first-page":"41","article-title":"The side effects of gonadotropin releasing hormone analog (diphereline) in treatment of idiopathic central precocious puberty","volume":"51","author":"Z Karamizadeh","year":"2013","journal-title":"Acta Med Iran"},{"issue":"2","key":"pone.0327842.ref048","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1042\/cs1040195","article-title":"Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia","volume":"104","author":"F Dockery","year":"2003","journal-title":"Clin Sci (Lond)"},{"issue":"12","key":"pone.0327842.ref049","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1592\/phco.28.12.1511","article-title":"Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer","volume":"28","author":"PE Kintzel","year":"2008","journal-title":"Pharmacotherapy"},{"key":"pone.0327842.ref050","doi-asserted-by":"crossref","first-page":"678797","DOI":"10.3389\/fendo.2021.678797","article-title":"GnRHa\/Stanozolol Combined Therapy Maintains Normal Bone Growth in Central Precocious Puberty","volume":"12","author":"S Zhu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0327842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T17:42:25Z","timestamp":1752255745000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0327842"}},"subtitle":[],"editor":[{"given":"Arturo","family":"Aguilar-Rojas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":50,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0327842","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]}}}